Recently, Beijing Higher People’s Court has made the final judgment to maintain the No. 20015 Invalidation Decision by the Patent Reexamination Board of SIPO, and all the claims of the patent Moxifloxacin hydrochloride and sodium chloride injection of Bayer were invalidated. On behalf of Peking University International Hospital Group, Ltd., Linda Liu & Partners filed a request to invalidate the Patent Moxifloxacin hydrochloride and sodium chloride injection in April 2012. The Patent Reexamination Board of SIPO made a decision that the whole patent was invalidated. Bayer was unsatisfied with the decision and appealed the case to the court of the first instance and the second instance. The case has been settled after three years and our firm won the case for client finally based on careful and full preparation and cooperation with our client during the invalidation procedure and the administrative litigation
As the relevant drugs with this patent have great market value, the invalidation decision of this patent has drawn wide attention from pharmaceutical enterprises in China.

Time: June 11rd, 2015
Source: Linda Liu & Partners